Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Akebia Therapeutics (NQ: AKBA )

0.9860 +0.0960 (+10.79%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,832,233
Open 0.8500
Bid (Size) 0.9700 (2)
Ask (Size) 0.9850 (31)
Prev. Close 0.8900
Today's Range 0.8400 - 0.9940
52wk Range 0.2410 - 2.930
Shares Outstanding 174,537,458
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Planned Government Move To Expand Access To Drugs For End-Stage Renal Disease Patients Could Shine The Spotlight On Unicycive
In the U.S., reimbursement of dialysis expenses by the Centers for Medicare & Medicaid Services (CMS) is done using a prospective payment system (PPS) which enables the payout of a predetermined amount... 
Via Benzinga

Performance

YTD
+58.39%
+58.39%
1 Month
+58.39%
+58.39%
3 Month
+245.84%
+245.84%
6 Month
+140.49%
+140.49%
1 Year
-47.27%
-47.27%

More News

Read More
Looking Into Akebia Therapeutics's Return On Capital Employed
Via Benzinga
Akebia Therapeutics Earnings Preview
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells
Via TheNewswire.com
Akebia Therapeutics Return On Capital Employed Insights
Via Benzinga
Akebia's Anemia Drug Disappoints In Mid-Stage COVID-19 Study
Via Benzinga
Akebia Therapeutics: Q2 Earnings Insights
Via Benzinga
Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells
Via Benzinga
Why Missfresh Shares Are Trading Lower; Here Are 30 Stocks Moving Premarket
Via Benzinga
Why Kiora Pharmaceuticals Is Trading Lower By Around 22%; Here Are 26 Stocks Moving Premarket
Via Benzinga
How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication
Via News Direct
How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication
Via TheNewswire.com
Exposures Product Safety
How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication
Via Benzinga
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
Via Benzinga
Why Amazon Is Trading Higher By 12%: Here Are 23 Stocks Moving Premarket
Via Benzinga
Accolade Shares Jump Around 29%, Here's 75 Biggest Movers From Friday
Via Benzinga
REV Stock Moves Amid Revlon Bankruptcy, Short Squeeze Hopes
Via InvestorPlace
U.S Stocks Turn Lower; Dow Tumbles Over 100 Points
Via Benzinga
Why Is Akebia Therapeutics Surging By 28%? 48 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why Is Akebia Therapeutics (AKBA) Stock Up 14% Today?
Via InvestorPlace
Why U.S. Stocks Are Trading Higher, Manufacturing Report And More
Via Benzinga
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.